Rocket
Premium
Excel Add-In
International
Tools
Dashboard
Screener
Spinoffs
IPOs
Register
Alerts
Sign In
Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Holdings
Ownership
Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
CC transcript
Appointed director
NEUROCRINE BIOSCIENCES INC (NBIX)
Create:
Alert
All
|
News
|
Filings
Date Filed
Type
Description
10/06/2023
8-K
Other Events Interactive Data
10/05/2023
8-K
Other Events, Financial Statements and Exhibits Interactive Data
Docs:
"
Neurocrine Biosciences Announces Phase 3 Pediatric Study Results of Crinecerfont in Children and Adolescents for the Treatment of Congenital Adrenal Hyperplasia Met Primary and Key Secondary Endpoints
"
10/02/2023
144
Form 144 - Report of proposed sale of securities:
08/22/2023
144
Form 144 - Report of proposed sale of securities:
08/22/2023
144
Form 144 - Report of proposed sale of securities:
08/22/2023
144
Form 144 - Report of proposed sale of securities:
08/22/2023
144
Form 144 - Report of proposed sale of securities:
08/22/2023
144
Form 144 - Report of proposed sale of securities:
08/22/2023
144
Form 144 - Report of proposed sale of securities:
08/22/2023
144
Form 144 - Report of proposed sale of securities:
08/22/2023
144
Form 144 - Report of proposed sale of securities:
08/22/2023
144
Form 144 - Report of proposed sale of securities:
08/22/2023
144
Form 144 - Report of proposed sale of securities:
08/01/2023
S-8
Form S-8 - Securities to be offered to employees in employee benefit plans:
08/01/2023
10-Q
Quarterly Report for the period ended June 30, 2023
08/01/2023
8-K
Quarterly results
07/13/2023
8-K
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
07/11/2023
8-K
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs:
"
BYLAW AMENDMENT
"
05/19/2023
8-K
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs:
"
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
"
05/03/2023
10-Q
Quarterly Report for the period ended March 31, 2023
05/03/2023
8-K
Quarterly results
05/01/2023
144
Form 144 - Report of proposed sale of securities:
04/24/2023
144
Form 144 - Report of proposed sale of securities:
04/19/2023
144
Form 144 - Report of proposed sale of securities:
04/18/2023
144
Form 144 - Report of proposed sale of securities:
04/06/2023
ARS
Form ARS - Annual Report to Security Holders:
04/05/2023
DEFA14A
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/05/2023
DEF 14A
Form DEF 14A - Other definitive proxy statements:
02/24/2023
SC 13D/A
NEUROCRINE BIOSCIENCES INC reports a 19.9% stake in VOYAGER THERAPEUTICS, INC.
02/10/2023
8-K
Quarterly results
02/09/2023
10-K
Annual Report for the period ended December 31, 2022
02/09/2023
SC 13G/A
VANGUARD GROUP INC reports a 9.7% stake in Neurocrine Biosciences Inc.
02/09/2023
SC 13G/A
JANUS HENDERSON GROUP PLC reports a 2.5% stake in NEUROCRINE BIOSCIENCES, INC.
02/06/2023
8-K
Quarterly results
Docs:
"
Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2022 Financial Results and Provides Financial Expectations for 2023
"
Next >>
Rocket Data Systems, Inc. © 2019 |
Contact Us
|
Data Disclaimer
|
Terms of Use
|
Privacy